Today's Breaking News
- Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
- Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B
- Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Latest R&D and Business News
- Biomarkers Offer Personal Touch to Patient Treatment
- Drug Research in Asia Goes Native
- R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in US for the Treatment of Severe Dry Eye
- Vortioxetine clinical phase III data show significant improvement in symptoms of major depression
- Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
- AREVA Med Presents Pharmacokinetics Data From Phase 1 Clinical Trial at SNMMI
- A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing
- AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
- Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
- Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
- Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria